Therapeutic and prevention strategies against human enterovirus 71 infection

doi:10.5501/wjv.v4.i2.78

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11371)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

703

WORD

419

HTML

5091

Tables (1-3)

288

Sum=6501

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

721

Download

1416

Sum=2137

Publishing Process of This Article

Item

Count

Browse

1240

Download

1493

Sum=2733

May 12, 2015 (publication date) through Feb 21, 2025

Times Cited of This Article

Times Cited (14)

Journal Information of This Article

Publication Name

World Journal of Virology

ISSN

2220-3249

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Virology. May 12, 2015; 4(2): 78-95
Published online May 12, 2015. doi: 10.5501/wjv.v4.i2.78

Table 3 Comparison of human enterovirus 71 vaccine strategies

Vaccines	Tested	Advantages	Disadvantages	Ref.
Live-attenuated vaccine	In vitro / in vivo	Broad spectrum, low cost	Incomplete attenuation	[143-149]
Inactivated vaccine	In vitro / in vivo / clinical trial	Inability to replicate	High cost	[150-162]
Subunit vaccine	In vitro / in vivo	Safe to use	Low immunogenicity	[153,154,163-178]
Synthetic peptides	In vitro / in vivo	Small and safe to use	Low immunogenicity, escape mutants	[94,179-181]
Virus-like particles	In vitro / in vivo	Safe to use	Unstable, need purification, high cost	[162,182-185]
DNA vaccine	In vitro / in vivo	Most resemble native virus, fast production, low cost, can be manipulated	Low neutralising effect	[153,186-190]

Citation: Kok CC. Therapeutic and prevention strategies against human enterovirus 71 infection. World J Virology 2015; 4(2): 78-95
URL: https://www.wjgnet.com/2220-3249/full/v4/i2/78.htm
DOI: https://dx.doi.org/10.5501/wjv.v4.i2.78